Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined With S-1 in Patients With Advanced Pancreatic Cancer: A Prospective Study.
Phase of Trial: Phase I/II
Latest Information Update: 19 Jan 2018
Price : $35 *
At a glance
- Drugs Dendritic cell-activated cytokine-induced killer cells (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Jan 2018 Status changed from recruiting to completed.
- 03 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.